Poll
Are gene-editing startups overhyped given current clinical trial failures?
With recent high-profile clinical trial failures for CRISPR-based therapies, investors and scientists are questioning whether the valuation of gene-editing startups reflects realistic timelines. Share your take on whether the hype is justified or if the sector needs a reset.
Options
Live results
Vote first to see results.
Emoji reactions
No reaction selected.
Comments
Please sign in to comment.
Share / embed
Quick info
- How do I vote in the "Are gene-editing startups overhyped given current clinical trial failures?" poll?
- Select one option on the page to cast your vote; results update with community votes in real time.
- Can I view results without voting?
- Yes. Use the "I don't know / Show results" option, or access the results summary after voting.
Similar polls
Up to 10 suggestions from the same category and shared tags, sorted by vote count; this poll is excluded.
From the same category
Basic Sciences and BiotechnologyThe same site category as this poll.
- Is learning basic biology still useful now that AI can answer everything?
- Would you switch from E. coli to yeast expression systems for higher protein yield?
- Can gene editing really fix our food supply as climate change worsens?
- Is CRISPR-based editing too reckless for human trials, or are ethical fears holding back a revolution?
- Is synthetic biology overhyped or the next big thing in basic sciences?
- Have peer-reviewed papers become a popularity contest for novel results rather than a reliable foundation for reproducible science?
- Do synthetic biology startups add real value, or mostly hype hoping for a patent sell-off?
- Should we embrace dangerous gain-of-function research or is the pandemic risk too high to justify it?
- Are "natural" biotech products safer, or is that just a marketing lie?
- Do you trust AI-generated drug candidates more than those from traditional screening methods?
TrendVersus.com · live data